ArticleEpilepsia2025
Ten-year projection of adult epilepsy burden in Australia.
Article in Epilepsia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Forecasting the prevalence of epilepsy in low- and middle-income countries to 2050 using a hybrid deep neural network-transformer modeling framework: insights from the Global Burden of Disease Study 2023.Military Medical Research · 2026Article
- Ten-year projection of adult epilepsy burden in Australia.Epilepsia · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveThe World Health Organization's Intersectoral Global Action Plan on Epilepsy and Other Neurological Disorders calls for more epilepsy care centers, but a population-level estimate of epilepsy's projected burden to justify this investment from a societal perspective is lacking. We aimed to project the burden of epilepsy using dynamic life table modeling including number of deaths, years of life, quality-adjusted life years (QALYs), productivity-adjusted life years (PALYs), health care costs, and number of people to be screened for surgical eligibility in the Australian adult population (aged 18-80 years) from 2024 to 2033.
methodsA dynamic model was developed to capture incident and prevalent epilepsy in Australia, using five health states: not seizure-free non-drug resistant (NSF-NDRE), seizure-free non-drug resistant (SF-NDRE), not seizure-free drug resistant (NSF-DRE), seizure-free drug-resistant (SF-DRE), and death in 1-year cycles. The inputs came from published studies, Glosgow cohort study and from the Australian Epilepsy Project.
resultsIn 10 years, 82 723 Australian adults had incident epilepsy, whereas 125 223 formed the prevalent cohort. Over 10 years, the epilepsy population experienced 15 227 deaths and accrued 1 209 280 years of life, distributed as 23.6% NSF-NDRE, 58.3% SF-NDRE, 15.8% NSF-DRE, and 2.1% SF-DRE. The population accrued 992 812 QALYs and 442 600 PALYs. Total health care costs reached $14.2 billion US dollars (USD), of which NSF-DRE contributed 35%. Uncontrolled seizures resulted in the loss of 84 881 QALYs, 19 333 PALYs, $4.5 billion USD, and 4603 lives. A total of 10 665 individuals were eligible for surgical evaluation, with an additional 383 projected annually through 2033. SIGNIFICANCE: This dynamic life table model, based on the current standard of care for epilepsy, demonstrates quality of life impact, productivity loss, and cost burden due to uncontrolled seizures and drug resistance, supporting the need for further investment in epilepsy care. This approach can be applied to other countries to inform policy decisions in epilepsy from a societal perspective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.